No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Accepts sBLA for Genentech/Roche’s Columvi® Combination Therapy
On 4 October 2024, Genentech and Roche announced that the US FDA has accepted Roche’s supplemental biologics licence application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people with relapsed or...